Skip to Main Content


The multidisciplinary Yale-ILD Center was established in 1997 to address the needs of these patients. The Center offers patients significant expertise and support in multiple areas, including treatment of complex lung diseases, the opportunity to participate in clinical and translational studies, and the chance to receive experimental therapy. We also work tirelessly to conduct research into the causes and potential cures for ILD and participate wholeheartedly in the education and support of patients, providers, and caregivers.

The Yale-ILD Center is also a multidisciplinary program in which pulmonologists with expertise in ILD are joined by specialty-trained pulmonary pathologists, chest radiologists, rheumatologists and occupational medicine physicians. Support is also provided by a dedicated physician extender. The weekly, multidisciplinary ILD Center conference is an opportunity for patient cases to receive an expert consensus opinion in accordance with nationally published guidelines.


If you have questions, please call our clinic at 203-495-2410, or email

Clinical Program

The Yale-ILD Center is a member of the Pulmonary Fibrosis Foundation Clinical Care Network and is part of Yale’s Scleroderma Foundation Clinical Care Center and we collaborate with physicians across the country to provide outstanding care to patients with all forms of ILD with a special focus on Idiopathic Pulmonary Fibrosis (IPF) and Scleroderma-associated Interstitial Lung Disease (SSc-ILD). We care for patients with all forms of ILD including idiopathic pulmonary fibrosis (IPF), ILD associated with autoimmune disorders, occupational lung disease and sarcoidosis. We see patients from all over the northeast and patients often travel to our center from throughout the United States, and abroad, to be evaluated and treated at a tertiary referral center with exceptional experience with these diseases.


The Yale-ILD Center houses an impressive research infrastructure that is aimed at understanding the role of dysregulated repair responses in the development, maintenance, progression, and perhaps regression of pulmonary fibrosis. These studies are performed using animal modeling combined with studies of primary human biospecimens obtained from subjects recruited from our center, from lung tissue obtained from the Rapid Autopsy Program that was instituted this year by Dr. Herzog, and in novel ex vivo studies using bioengineering based models that were developed by the Herzog and Kaminski Labs. Investigators in the Center possess an impressive NIH portfolio comprised of both R01 and U01 level funding as well as several substantial collaborations with industry. The Center has also published many manuscripts in the last year both as primary investigators and as collaborating partners.